Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 293 Companies   490 Products   490 Products   199 Mechanisms of Action   25 Trials   7787 News 


«12...2930313233343536373839...156157»
  • ||||||||||  DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
    Enrollment open:  Post Marketing Surveillance (PMS) Study of Ryzodeg (clinicaltrials.gov) -  Aug 29, 2016   
    P=N/A,  N=1000, Enrolling by invitation, 
    Active, not recruiting --> Enrolling by invitation
  • ||||||||||  tibulizumab (ZB-106) / Zura Bio
    Trial primary completion date:  A Study of LY3090106 in Participants With Sj (clinicaltrials.gov) -  Aug 29, 2016   
    P1,  N=32, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Apr 2017 --> Jan 2018
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Trial completion, Review, Enrollment change, Trial primary completion date:  REALIZE: Tecfidera Lymphocyte Chart Review (clinicaltrials.gov) -  Aug 26, 2016   
    P=N/A,  N=483, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | N=1500 --> 483 | Trial primary completion date: Nov 2015 --> Feb 2016
  • ||||||||||  lacosamide / Generic mfg.
    Enrollment change, Trial withdrawal, Trial primary completion date:  Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: (clinicaltrials.gov) -  Aug 26, 2016   
    P2,  N=0, Withdrawn, 
    Trial primary completion date: Dec 2010 --> Jan 2012 N=50 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Nov 2016 --> Aug 2016
  • ||||||||||  Trial completion, Phase classification, Enrollment change, Trial primary completion date:  Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs (clinicaltrials.gov) -  Aug 25, 2016   
    P1,  N=36, Completed, 
    N=50 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Nov 2016 --> Aug 2016 Enrolling by invitation --> Completed | Phase classification: PN/A --> P1 | N=75 --> 36 | Trial primary completion date: Apr 2010 --> Sep 2011
  • ||||||||||  Enrollment closed, Enrollment change:  ENHANCE: MS Symptom Management Study (clinicaltrials.gov) -  Aug 24, 2016   
    P=N/A,  N=37, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=30 --> 37
  • ||||||||||  Humira (adalimumab) / AbbVie
    Trial primary completion date, Real-world evidence, Real-world:  Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan (clinicaltrials.gov) -  Aug 23, 2016   
    P=N/A,  N=100, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Oct 2016 Trial primary completion date: Nov 2016 --> Jan 2018
  • ||||||||||  Trial completion:  NIDOCIGA: IgA Nephropathy, Lymphocyte Homing and IgA Class Switch (clinicaltrials.gov) -  Aug 22, 2016   
    P=N/A,  N=72, Completed, 
    Recruiting --> Completed | N=70 --> 20 | Trial primary completion date: Dec 2016 --> Feb 2016 Recruiting --> Completed
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) -  Aug 22, 2016   
    P=N/A,  N=34, Terminated, 
    Recruiting --> Completed N=50 --> 34 | Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2016; PI is moving to a different institution.
  • ||||||||||  Orencia (abatacept) / BMS
    Trial primary completion date:  Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL (clinicaltrials.gov) -  Aug 22, 2016   
    P=N/A,  N=370, Active, not recruiting, 
    N=50 --> 34 | Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2016; PI is moving to a different institution. Trial primary completion date: Jun 2016 --> Sep 2016
  • ||||||||||  Trial primary completion date:  NeuroSenSS: Primary Sj (clinicaltrials.gov) -  Aug 22, 2016   
    P=N/A,  N=55, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Sep 2015 --> Sep 2016
  • ||||||||||  M923 (adalimumab biosimilar) / J&J
    Enrollment closed, Enrollment change:  Usability of an AI for M923 in Subjects With Moderate to Severe RA (clinicaltrials.gov) -  Aug 19, 2016   
    P3,  N=51, Active, not recruiting, 
    Trial primary completion date: Sep 2015 --> Sep 2016 Recruiting --> Active, not recruiting | N=32 --> 51
  • ||||||||||  Trial completion, Enrollment change, Trial initiation date, Trial primary completion date:  Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis (clinicaltrials.gov) -  Aug 19, 2016   
    P=N/A,  N=19, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=25 --> 19 | Initiation date: Jun 2015 --> Sep 2015 | Trial primary completion date: May 2016 --> Dec 2015
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    New trial:  Late Night Snack and Insulin Glargine (clinicaltrials.gov) -  Aug 19, 2016   
    P=N/A,  N=20, Completed, 
  • ||||||||||  Trial initiation date, Trial primary completion date:  DiaCon Dual-Hormone Closed-Loop Glucose Control (clinicaltrials.gov) -  Aug 16, 2016   
    P2/3,  N=13, Not yet recruiting, 
    Active, not recruiting --> Completed Initiation date: May 2016 --> Oct 2016 | Trial primary completion date: Jun 2016 --> Jun 2017
  • ||||||||||  Trial completion:  Progressive Resistance Exercise in Rheumatoid Arthritis (clinicaltrials.gov) -  Aug 15, 2016   
    P4,  N=60, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Apr 2016 Recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Telehealth Intervention for Youth With T1DM (clinicaltrials.gov) -  Aug 15, 2016   
    P=N/A,  N=32, Completed, 
    Recruiting --> Completed Recruiting --> Completed | N=110 --> 32 | Trial primary completion date: Dec 2014 --> May 2014
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial primary completion date:  RICE: Remission by Intra-articular Injection Plus CErtolizumab (clinicaltrials.gov) -  Aug 13, 2016   
    P2,  N=48, Recruiting, 
    Recruiting --> Completed | N=110 --> 32 | Trial primary completion date: Dec 2014 --> May 2014 Trial primary completion date: Dec 2016 --> Dec 2017